| Autor: |
V, Havu, H, Heikkilä, K, Kuokkanen, M, Nuutinen, T, Rantanen, S, Saari, S, Stubb, R, Suhonen, K, Turjanmaa |
| Rok vydání: |
2000 |
| Předmět: |
|
| Zdroj: |
The British journal of dermatology. 142(1) |
| ISSN: |
0007-0963 |
| Popis: |
In a randomized, double-blind, double-placebo, multicentre study, terbinafine 250 mg daily for 12 weeks was compared with fluconazole 150 mg once weekly for 12 or 24 weeks in the treatment of onychomycosis. A total of 137 patients with culture-confirmed onychomycosis was divided into three groups: group A received terbinafine for 12 weeks, group B received fluconazole for 12 weeks, while group C received fluconazole for 24 weeks. At completion of the study (week 60), the mycological cure rate was higher in the terbinafine group than in the fluconazole groups: 89% vs. 51% and 49%, respectively (P0.001). The length of unaffected nail increased until week 24 in group B and until week 36 in group C, but was still increasing in group A at the final visit (week 60). Complete clinical cure of the target nail at week 60 was 67% in the terbinafine group, compared with 21% and 32% in the fluconazole groups, respectively. The incidence of adverse events was low for both study agents. We conclude that terbinafine 250 mg daily for 12 weeks is significantly more effective in the treatment of onychomycosis than fluconazole 150 mg once weekly for either 12 or 24 weeks. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text